CD19 and amyotrophic lateral sclerosis: The immunophenotypic changes measured in ALS patients included markers of identity or function (i.e. CD19+IgM+), differentiation (i.e. stem cell memory CD8+ cells) or activation (i.e. CD25+CD8+ cells).